Biodexa Pharmaceuticals Plc (BDRX) Form 6-K — Oct 14, 2026
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced enrollment of its 100th patient in the Serenta registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. The trial is recruiting at 29 sites across the US and Europe, with two Canadian sites expected shortly, targeting 168 subjects randomized 2:1 drug to placebo. The company said that based on the current rate of PFS event accrual, the pre-specified futility analysis (after 25 PFS events) could occur early next year and database lock (after 75 events) potentially around the end of next year — both significantly sooner than originally anticipated.
Key figures
- Clinical sites
- 29
- Cprit grant usd
- $20 million
- Patients enrolled
- 100
- Planned enrollment
- 168
- Randomization ratio
- 2:1 drug:placebo
- Database lock pfs events
- 75
- Futility analysis pfs events
- 25
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.